NCT05465681View on ClinicalTrials.gov

Study of HR20013 for Injection in Patients With Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

January 13, 2023

Study Completion Date

January 13, 2023

Conditions
Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
Interventions
DRUG

HR20013 for injection；dexamethason

"HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy.~dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy"

Trial Locations (1)

510000

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY